Product Details
| Product Name:
CD73-IN-11 |
CAS No.:
2766566-11-2 |
| Supply Ability:
10g |
Release date:
2025/10/27 |
Product Introduction
Bioactivity
| Name | CD73-IN-11 |
| Description | CD73-IN-11 is able to used for tumor-related diseases medicament preparing. CD73-IN-11 is an effective CD73 inhibitor. CD73 can catalyze the production of adenosine from extracellular 5'-phosphate adenosine (5'-AMP) which induce immunosuppression and promote tumor proliferation and/or metastasis [1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Inhibitors Related | Mupadolimab | Oleclumab | MethADP sodium salt | AMPCP | AB-680 | CD73-IN-1 | MethADP | CD73-IN-4 | OP-5244 sodium | PSB-12379 ditriethylamine salt | CD73-IN-12 | CD73-IN-3 |
Company Profile Introduction
TargetMol Chemicals Inc. is headquartered in Boston, MA, and specializes in products and services that serve the research needs of chemical and biological scientists worldwide. With a client base in 40+ countries, TargetMol has evolved into one of the biggest global research suppliers for compound libraries and small molecule compounds.
170+ Compound Libraries, 10000+ Noval Small Molecucles,16000+ Nature Compounds
TargetMol diligently updates and offers over 170 types of compound libraries and a wide range of high-quality research chemicals, including inhibitors, activators, natural products, peptides, antibodies , and novel life-science kits for laboratory and scientific use. In addition, our lab allows us to conduct CADD (computer-aided drug design) and chemical synthesis to meet the customization needs of our clients.
You may like
-
CAS:2763710-08-1
$2785.00 / 50mg
-
CAS:2766565-91-5
$2785.00 / 50mg
-
CAS:2766565-88-0
$2785.00 / 50mg
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
$68.00/1mg |
VIP4Y
|
TargetMol Chemicals Inc.
|
2025-09-16 |
|
|
$68.00/1mg |
VIP6Y
|
TargetMol Chemicals Inc.
|
2025-09-16 |
|
|
$5.00/1Box |
VIP1Y
|
Hebei Jiafan Trading Company Limited
|
2025-03-11 |